Brain 17 Vienna

Addition of EGFR inhibitors to WBRT does (probably) not prolong survival

WBRT + gefitinib or temozolomide • Gefitinib: median OS 6.3 months • Temozolomide: median OS 4.9 months • Fatigue as major side effect

WBRT and SRS + erlotinib or temozolomide in patients with < 3 brain mets • WBRT and SRS: median OS 13.4 months • Addition of temozolomide: median OS 6.3 months • Addition of erlotinib: median OS 6.1 months • Increased toxicity in the gefitinib and temozolomide arm

Pesce et al. Eur J Cancer 2012 Sperduto et al. Int J Radiat Oncol Biol Phys 2013